Caprock Group LLC Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Caprock Group LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,727 shares of the company’s stock, valued at approximately $236,000.

A number of other hedge funds have also modified their holdings of NBIX. Brooklyn Investment Group boosted its stake in shares of Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Blue Trust Inc. lifted its holdings in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. R Squared Ltd acquired a new position in Neurocrine Biosciences in the fourth quarter valued at about $61,000. UMB Bank n.a. boosted its position in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock valued at $62,000 after buying an additional 309 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Neurocrine Biosciences during the third quarter worth about $63,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 222,693 shares of company stock worth $32,718,279. Insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. UBS Group upped their price objective on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Raymond James reaffirmed an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Finally, Wedbush restated an “outperform” rating and issued a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $166.85.

Neurocrine Biosciences Stock Down 0.5 %

NASDAQ:NBIX opened at $150.51 on Friday. The company has a market cap of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The business has a 50 day moving average price of $138.41 and a two-hundred day moving average price of $131.64.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 3.92 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.